Amgen Clinical Trial Pipeline — 163 Active Studies

Phase 1: 45, Phase 2: 32, Phase 3: 69, Other: 17

Amgen's pipeline is defined by three breakthrough areas: targeted oncology (KRAS G12C inhibition with Lumakras/sotorasib, BiTE bispecific T-cell engagers led by Blincyto), cardiometabolic (Repatha/evolocumab for LDL lowering, olpasiran for Lp(a)), and inflammation/rare disease (Tezspire/tezepelumab for severe asthma, Otezla/apremilast). The KRAS franchise represents Amgen's most watched competitive program — Lumakras is the first approved KRAS inhibitor, and Amgen's pipeline of next-generation KRAS G12C inhibitors and KRAS combinations is closely tracked by the oncology community. Their BiTE platform (multiple CD19, BCMA, and other targets) continues generating new programs in hematology.

• Oncology (KRAS G12C, BiTE T-cell engagers)
• Cardiometabolic (PCSK9, Lp(a), HCM)
• Inflammation (TSLP, IL-5)
• Rare bone disease (denosumab)
• Hematology (BiTE, lymphoma)

• Lumakras (sotorasib) — KRAS G12C inhibitor, NSCLC/CRC
• Blincyto (blinatumomab) — CD19xCD3 BiTE, ALL/NHL
• Repatha (evolocumab) — PCSK9 inhibitor, cardiovascular
• Tezspire (tezepelumab) — TSLP, severe asthma
• Olpasiran — siRNA, Lp(a) lowering
• AMG 193 — MTAP-deletion solid tumors

Amgen's KRAS combination trials are the most watched oncology programs for anyone developing drugs in KRAS-altered cancers (particularly NSCLC, CRC, and pancreatic cancer). New Lumakras combination registrations signal competitive threat to programs developing SOS1, SHP2, or other KRAS-pathway inhibitors.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Amgen's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: Amgen may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.